Science That Powers Progress
Robust Science Needs Robust Tools That Make It Easier to Move From Research to Results
StimulusBio develops practical, effective technologies that help life science teams solve real-world problems. Our platform leverages biologically-driven design to enable discovery in diagnostics and cell & gene therapy by reducing manufacturing barriers, improving consistency, and speeding up clinical progress.
Accelerate Cell and Gene Therapy Development with Unmatched Flexibility
Our products seek to overcome critical barriers to widespread use of cell and gene therapies: scalability, vein to vein time, and product consistency. By leveraging our biocompatible platform based on programmable surface engineering (sbPCI), you can streamline complex workflows to more efficiently translate discoveries into clinical solutions.
CellPilot™
Precise, Customizable Cell Control in Less Time
Rapid configuration and high-throughput investigation drops development timelines from months to weeks. Using modular presentation of antigens, co-stimulatory molecules, and cytokines on non-immunogenic presenting cells, our high-throughput screening platform delivers a transformative solution for tailored immune cell characterization and behavior.
- High-throughput screening and characterization
- Scalable directed design
- Applicable across immune cell types
The CellPilot platform is uniquely suited to drive CGT workflow improvements where early and actionable information can improve outcomes by enabling:
- Optimization strategies to overcome patient variability
- Custom formulations for desired cell expansion
- Consolidated testing for improved CMC assays
Provide Next-Level Assay Control
Advanced assays are often plagued by variability in sample prep, diverse detection methods, and insufficient quantification tools. StimulusBio’s next-generation standards give scientists a consistent, scalable way to work with critical evolving technologies.
Cross-Modality EV Standards
A modular and versatile solution for extracellular vesicle (EV) standardization that enables multiplexed detection, quantitative yield quantification, and cross-assay validation. StimulusBio EV Standards maximize data reliability and reproducibility by incorporating rigorously defined fluorophores and genetic markers, provided at calibrated sizes and concentrations.
- Universal Cross-Platform Standardization to ensure data consistency by enabling direct reference and precise comparison across all major analytical platforms, including flow cytometry, qPCR, ELISA, and microscopy.
- Quantitative Assessment using spike-in standards that offer a known quantity of reference material to assess experimental accuracy and consistency.
- Integrated Multiplex Measurement for simultaneous quantification of EV count, size, intensity, load, and genetic targets in a single assay.
- Customizable and Workflow-Ready with seamless integration into diverse workflows, supporting robust validation and accelerated assay development with tailored fluorophores and genetic elements specific to your research needs.
The Power Behind Our Products
StimulusBio’s Programmable Cellular Interface (sbPCI) technology empowers scientists to tailor the presentation of cellular stimulatory molecules. The advantage comes in the ability to quantitatively produce desired surface activity on a presenting cell and use intracellular communication to direct the phenotype of the target cell.
This cutting-edge approach accelerates development and streamlines cellular communication by eliminating the need for genetic modification. sbPCI promises to improve outcomes while driving consistency and streamlining complex workflows in cell therapy research.
Built as a modular system, sbPCI provides precise control over molecular configurations. This enables accurate and controllable introduction of bioactive molecules to an immune-compatible base. Researchers can engineer the surface to present desired phenotypes that match cell type or interaction goals, making it easier to replicate physiological conditions without relying on genetic modification.
The inherent flexibility of this design reduces timelines and improves the consistency of multiple applications ranging from targeted cellular activation to enhanced cell screening.